Bavarian Nordic (BATS-CHIXE:BAVAC) - Aktienkurs, Nachrichten und Analyse

BAVAC Aktienübersicht

Bavarian Nordic A/S entwickelt, produziert und vermarktet lebensrettende Impfstoffe.

BAVAC grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	4/6
Künftiges Wachstum	1/6
Vergangene Leistung	4/6
Finanzielle Gesundheit	6/6
Dividenden	0/6

Belohnungen

66.6% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 5.94% pro Jahr

Die Erträge stiegen im vergangenen Jahr um 227.1%

Risikoanalyse

Aktien sind hochgradig illiquide

Große einmalige Posten, die sich auf die Finanzergebnisse auswirken

Bavarian Nordic A/S Wettbewerber

Genus

LSE:GNS

UK£1.1b

Bioventix

AIM:BVXP

UK£231.0m

HUTCHMED (China)

AIM:HCM

UK£2.4b

Ergomed

AIM:ERGO

UK£701.1m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Bavarian Nordic
Historische Aktienkurse
Aktueller Aktienkurs	DKK 156.90
52-Wochen-Hoch	DKK 175.63
52-Wochen-Tief	DKK 135.38
Beta	1.42
11 Monat Veränderung	0%
3 Monate Veränderung	1.57%
1 Jahr Veränderung	-26.82%
33 Jahre Veränderung	-41.03%
5 Jahre Veränderung	-4.39%
Veränderung seit IPO	142.32%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	BAVAC	GB Biotechs	GB Markt
7D	0%	-2.4%	0.6%
1Y	-26.8%	-25.6%	8.3%

Rendite im Vergleich zur Industrie: BAVAC unter dem Niveau der Branche UK Biotechs , die im vergangenen Jahr eine Rendite von -25.7% erzielte.

Rendite vs. Markt: BAVAC hinter dem Markt UK zurück, der im vergangenen Jahr eine Rendite von 7 erzielte.

Preisvolatilität

Is BAVAC's price volatile compared to industry and market?
BAVAC volatility
BAVAC Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.3%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	11.2%
10% least volatile stocks in GB Market	2.7%

Stabiler Aktienkurs: BAVAC hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.

Volatilität im Zeitverlauf: Unzureichende Daten, um die Volatilitätsveränderung von BAVAC im vergangenen Jahr zu bestimmen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1992	1,381	Paul Chaplin	www.bavarian-nordic.com

Bavarian Nordic A/S entwickelt, produziert und vermarktet lebensrettende Impfstoffe. Das Unternehmen bietet nicht replizierende Pocken- und Affenpockenimpfstoffe unter den Namen IMVAMUNE, IMVANEX und JYNNEOS, Tollwutimpfstoff für den Menschen unter dem Namen Rabipur/RabAvert, Impfstoff gegen Zeckenenzephalitis unter dem Namen Encepur und Ebola-Impfstoff unter dem Namen MVABEA an. Darüber hinaus entwickelt das Unternehmen MVA-BN zur Behandlung von Pocken, MVA-BN RSV, das sich in der klinischen Phase III zur Behandlung des Respiratory Syncytial Virus befindet, sowie ABNCoV2, das die klinische Phase III zur Behandlung von SARS-CoV-2 abgeschlossen hat.

Bavarian Nordic A/S's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Bavarian Nordic im Vergleich zum Marktanteil des Unternehmens?
BAVAC grundlegende Statistiken
Marktanteil	DKK 12.22b
Gewinn(TTM)	DKK 984.37m
Umsatz(TTM)	DKK 6.64b

12.4x

Kurs-Gewinn-Verhältnis

1.8x

Kurs-Umsatz-Verhältnis

Ist BAVAC zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
BAVAC Gewinn- und Verlustrechnung (TTM)
Einnahmen	DKK 6.64b
Kosten der Einnahmen	DKK 2.04b
Bruttogewinn	DKK 4.60b
Sonstige Ausgaben	DKK 3.62b
Umsatz	DKK 984.37m

Zuletzt gemeldete Gewinne

Mar 31, 2024

Datum des nächsten Gewinnberichts

Aug 22, 2024

Gewinn per Aktie (EPS)	12.65
Bruttomarge	69.29%
Nettogewinnspanne	14.82%
Schulden/Eigenkapital-Verhältnis	0.2%

Wie hat sich BAVAC auf lange Sicht entwickelt?

Historische Performance und Vergleiche

BAVAC Aktienübersicht

Belohnungen

Risikoanalyse

Bavarian Nordic A/S Wettbewerber

LSE:GNS

UK£1.1b

AIM:BVXP

UK£231.0m

AIM:HCM

UK£2.4b

AIM:ERGO

UK£701.1m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

Less than half of directors are independent

Less than half of directors are independent

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Less than half of directors are independent

Less than half of directors are independent

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Less than half of directors are independent

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Full year 2022 earnings released: kr.4.90 loss per share (vs kr.7.37 loss in FY 2021)

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Less than half of directors are independent

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Chairman recently sold kr.508k worth of stock

Less than half of directors are independent

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Less than half of directors are independent

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Less than half of directors are independent

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2022

Less than half of directors are independent

Bavarian Nordic A/S Receives U.S. and Eu Approvals of Its Fill and Finish Vaccine Manufacturing Facility

Bavarian Nordic A/S Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox

Bavarian Nordic A/S Raises Earnings Guidance for the Financial Guidance for 2022

Less than half of directors are independent

Bavarian Nordic A/S Provides an Update on the Phase 3 Development of ABNCoV2, A VLP-Based, Non-Adjuvanted Covid-19 Booster Vaccine Candidate

Bavarian Nordic A/S Revises Revenue Guidance for the Year 2022

Bavarian Nordic A/S Raises Financial Guidance for the Year 2022

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic Reports Omicron Data from Phase 2 Trial of Its Covid-19 Booster Vaccine Candidate

Bavarian Nordic Announces Initiation of A Global Phase 3 Clinical Trial of Its RSV Vaccine Candidate in Older Adults

High number of new directors

Bavarian Nordic A/S Provides Revenue Guidance for the Full Year of 2022

Bavarian Nordic A/S Reports Additional Positive Phase 2 Results for Its Covid-19 Vaccine Candidate Ahead of Phase 3 Trial

Bavarian Nordic Announces Breakthrough Therapy Designation for Its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults

High number of new directors

Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base

Erträge & Einnahmen